DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL. (June 2017) - Pettengell, R.; Uddin, R.; Boumendil, A.; Robinson, S.P.; Smith, G.; Hawkins, T.; Metzner, B.; Caballero, M.D.; Tilly, H.; Romejko‐Jarosinska, J.; Bence‐Bruckler, I.; To, B.; et al.